Core Insights - The company is focusing on innovation-driven strategies in the "AI + health" sector, emphasizing long-term investment and market service [1] - The company has successfully passed the acceptance of a project for an "intelligent massage robot based on traditional Chinese medicine acupoint theory," which was approved by the Xiamen Science and Technology Bureau [1] - The company is establishing a "National Postdoctoral Research Station" and a "National Enterprise Technology Center" in collaboration with the "Chinese Academy of Sciences Haixi Research Institute" to develop core technologies for intelligent health service robots [1] - The company's product offerings include health massage products (massage chairs, small massage appliances) and health environment products (fresh air systems, air purifiers) [1] Financial Performance - In the first half of 2025, the company achieved revenue of 2.327 billion yuan, representing a year-on-year growth of 5.65% [1] - The company reported a net profit attributable to shareholders of 27 million yuan, with a year-on-year increase of 14.01% [1]

富国新兴产业股票A/B（001048）基金经理为孙权。 截至发稿，孙权累计任职时间3年210天，现任基金资产总规模77.5亿元，任职期间最佳基金回报 111.87%， 任职期间最差基金回报35.44%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 9月24日，荣泰健康涨5%，截至发稿，报36.72元/股，成交1.12亿元，换手率1.55%，总市值74.67亿元。 资料显示，上海荣泰健康科技股份有限公司位于上海市青浦区徐泾镇高光路169弄6栋02，成立日期2002 年11月15日，上市日期2017年1月11日，公司主营业务涉及按摩器具的设计、研发、生产和销售。主营 业务收入构成为：按摩椅96.12%，按摩小电器2.59%，其他(补充)1.00%，体验式按摩服务0.29%。 从荣泰健康十大流通股东角度 数据显示，富国基金旗下1只基金位居荣泰健康十大流通股东。富国新兴产业股票A/B（001048）二季 度新进十大流通股东，持有股数255.75万股，占流通股的比例为1.44% ...

9月23日，荣泰健康跌5.15%，截至发稿，报34.78元/股，成交1.53亿元，换手率2.13%，总市值70.73亿 元。荣泰健康股价已经连续3天下跌，区间累计跌幅8.32%。 从荣泰健康十大流通股东角度 数据显示，富国基金旗下1只基金位居荣泰健康十大流通股东。富国新兴产业股票A/B（001048）二季 度新进十大流通股东，持有股数255.75万股，占流通股的比例为1.44%。根据测算，今日浮亏损失约 483.36万元。连续3天下跌期间浮亏损失851.64万元。 责任编辑：小浪快报 富国新兴产业股票A/B（001048）成立日期2015年3月12日，最新规模31.37亿。今年以来收益70.57%， 同类排名108/4220；近一年收益163.48%，同类排名20/3814；成立以来收益280.2%。 截至发稿，孙权累计任职时间3年209天，现任基金资产总规模77.5亿元，任职期间最佳基金回报 105.39%， 任职期间最差基金回报34.81%。 资料显示，上海荣泰健康科技股份有限公司位于上海市青浦区徐泾镇高光路169弄6栋02，成立日期2002 年11月15日，上市日期2017年1月11日，公司主营业务涉及 ...

Core Viewpoint - OGAWA Intelligent Health Technology Group has showcased its strategic positioning and development in the health industry through recent investor meetings, highlighting its focus on health products and market potential [1] Group 1: Business Overview - The company primarily operates in health massage products, including massage chairs and small massage appliances, as well as health environment products like fresh air systems and air purifiers. In the first half of 2025, the revenue contribution from massage chairs, small massage appliances, health environment, and other categories was 44.23%, 30.64%, 15.30%, and 9.83% respectively [2] - The market potential is significant, particularly in East Asia and Southeast Asia, where traditional massage practices are prevalent. Developed regions like North America and Europe have also begun to recognize the health benefits of these products. The domestic market for massage health products has low penetration and concentration, indicating substantial growth potential as health demands rise and the population ages [2] Group 2: Financial Performance and Strategy - The company has experienced a decline in revenue and net profit due to global economic slowdown and weak consumer demand. However, it has implemented several strategies to enhance performance, including focusing on the health industry, increasing the share of its own brand revenue to over 50%, and achieving significant growth in the "OGAWA" brand [3] - The company is investing in technological innovation, particularly in AI technology and product development, with the introduction of a globally pioneering 5D core technology in high-end massage chairs. It is also expanding its marketing efforts and enhancing online competitiveness through targeted advertising and influencer collaborations [3] Group 3: Production and Innovation - The company’s factory in Vietnam has a production capacity of 5.4 million units per year for small massage appliances and health environment products, catering to overseas ODM clients. The company plans to adjust production based on market conditions [4] - In the AI sector, the company is developing a matrix of innovative technologies and smart products, including precise detection of massage intensity and adaptive control. It is also working on health service robots and new massage chair designs that feature advanced movement capabilities [4] Group 4: Financial Instruments - As of June 30, 2025, the remaining balance of the convertible bonds "OGAWA Convertible Bonds" was 458 million yuan, which is classified as a current liability due to its maturity in February 2026. The company has decided not to adjust the conversion price for the next six months [4]

证券代码：002614 证券简称：奥佳华 奥佳华智能健康科技集团股份有限公司 投资者关系活动记录表 编号：2025-05 投资者关系活动 类别 √ 特定对象调研 □ 分析师会议 □ 媒体采访 □ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他 参与单位名称及 人员姓名 2025 年 9 月 17 日 兴全基金：邓荃文； 2025 年 9 月 18 日 惠璞投资：徐克；天风资管：许磊涛；钧山资管：敖焱杰； 澜胜私募：刘凤山；北大纵横资本：曹铭；上海证券：葛博威； 厦门咸达：赵绪堂；光莆股份：施姗姗； 昆明经开：赵素君、李茹丹。 时间 2025 年 9 月 17 日（周三）上午 10:00； 2025 年 9 月 18 日（周四）上午 10:30 地点 厦门市湖里区安岭二路 31-37 号 8 楼 上市公司接待人 员姓名 曾建宝、陈艺抒、林秋燕、杨文为、陈晓瑜 投资者关系活动 主要内容介绍 一、投资者参观展厅并体验了核心产品 二、公司整体业务和战略规划概况介绍 三、互动交流摘要 1、公司主营业务各品类的占比情况？ 公司主要经营包括保健按摩（按摩椅、按摩小电器）、健康 环境（新风系统、空气净化器） ...

Company Overview - Rongtai Health's stock price increased by 2.00% on September 18, reaching 40.80 CNY per share, with a trading volume of 1.84 billion CNY and a turnover rate of 2.27%, resulting in a total market capitalization of 8.297 billion CNY [1] - The company specializes in the design, research and development, production, and sales of massage equipment, with its main revenue sources being massage chairs (96.12%), small massage appliances (2.59%), and other services (0.29%) [1] Financial Performance - For the first half of 2025, Rongtai Health reported a revenue of 810 million CNY, a year-on-year decrease of 1.78%, and a net profit attributable to shareholders of 85.3369 million CNY, down 23.35% year-on-year [2] - The company has distributed a total of 880 million CNY in dividends since its A-share listing, with 316 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for Rongtai Health was 13,400, a decrease of 33.34% from the previous period, while the average number of circulating shares per person increased by 50.02% to 13,254 shares [2] - Among the top ten circulating shareholders, the sixth largest is the Fu Guo New Emerging Industries Stock A/B, which holds 2.5575 million shares as a new shareholder [3] Market Activity - Rongtai Health's stock has seen significant price increases this year, with a total rise of 188.26%, including a 10.42% increase over the last five trading days and a 64.25% increase over the last 60 days [1] - The company has appeared on the trading leaderboard eight times this year, with the most recent appearance on September 9, where it recorded a net buy of -51.2146 million CNY [1]

每经头条（nbdtoutiao）——重大突破！中国这款新药，中美官方都认定有突破性疗效！世界肺癌大会 沸腾了 （记者 曾健辉） 每经AI快讯，奥佳华（SZ 002614，收盘价：6.89元）9月15日晚间发布公告称，公司第六届第十一次董 事会会议于2025年9月15日在厦门市湖里区安岭二路31-37号公司八楼会议室以现场+通讯相结合的方式 召开。会议审议了《关于补选第六届董事会薪酬与考核委员会委员的议案》等文件。 2025年1至6月份，奥佳华的营业收入构成为：按摩居室电器占比42.88%，按摩小电器占比29.7%，健康 环境产品占比14.84%，其他占比9.53%，其他业务占比3.05%。 截至发稿，奥佳华市值为43亿元。 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Views - The company's revenue performance has experienced a phase decline due to overseas demand and policy impacts, with a 1.78% year-on-year decrease in revenue for H1 2025 [2][4] - The company is a leading player in the domestic massage chair market and a significant global manufacturer, with a well-established R&D, industrial design, and quality control system [11] - The company is expected to see a recovery in demand, leading to a rapid rebound in growth, with projected net profits of 173 million, 199 million, and 224 million yuan for 2025, 2026, and 2027 respectively [11] Financial Performance Summary - For H1 2025, the company achieved operating revenue of 810 million yuan, a decrease of 1.78% year-on-year, and a net profit attributable to shareholders of 85.34 million yuan, down 23.35% year-on-year [2][4] - In Q2 2025, the company reported operating revenue of 415 million yuan, a decline of 2.14% year-on-year, and a net profit of 41.40 million yuan, down 14.81% year-on-year [2][4] - The company's gross margin decreased by 0.43 percentage points year-on-year in H1 2025, with a notable improvement in Q2 2025 where gross margin increased by 1.95 percentage points year-on-year [11] Product and Market Analysis - The revenue from massage chairs decreased by 0.36% year-on-year, while the revenue from massage small appliances fell by 14.71%. Conversely, experiential massage services grew by 10.34% [11] - Domestic business revenue increased by 16.92% year-on-year, while overseas business revenue declined by 13.24% [11] - The company is expanding its market presence, with positive growth in regions like Australia, Central Asia, and South Asia, while facing challenges in the U.S. market due to increased tariff costs [11]

Core Insights - The company, OJIAWA Intelligent Health Technology Group, engaged in a targeted investor research activity with four institutions to discuss business strategies, market environment, and tariff impacts [1][2]. Group 1: Domestic Market Strategy and Environment - The domestic massage and health product market has low penetration and concentration, but significant potential exists due to rising health demands, an aging population, and the increasing prevalence of sub-health among younger individuals. The massage chair market has seen a recovery in 2023, supported by the "old-for-new" subsidy policy. The company is innovating to meet consumer demands, enhancing product offerings, and focusing on brand marketing through flagship product promotions and collaborations with Olympic champions [3]. Group 2: U.S. Tariffs and Vietnam Production Capacity - The company's global business strategy is predominantly non-U.S., with U.S. sales accounting for less than 22% of total revenue in the first half of 2023. The Vietnam factory has a designed annual production capacity of 5.4 million units for massage small appliances and health environment products, which is gradually being put into operation. The company plans to adjust manufacturing orders based on market and international conditions to enhance supply chain risk management [4]. Group 3: Sales Expenses and Profitability - The company operates various health products and has driven growth through a dual strategy of global self-owned brands and ODM business. It invests heavily in sales resources to strengthen brand recognition, with several brands holding leading market shares. The focus will be on the health industry, enhancing core market competitiveness, accelerating product innovation, and improving operational resilience [5]. Group 4: R&D Investment Direction - The company prioritizes R&D innovation and is the only enterprise in the industry with seven national-level innovation platforms. It maintains high levels of R&D investment, following a strategy of "producing one generation, reserving one generation, researching one generation, and improving one generation." The focus is on cutting-edge health technologies, integrating AI and IoT for product upgrades, such as transitioning from the fifth generation 4D brushless variable frequency temperature-sensing core to the sixth generation 5D core flagship massage chair [6]. Group 5: Technology Layout Planning - The company aims to leverage technological innovation as a breakthrough for high-quality development, reinforcing core hardware advantages and increasing R&D investment in software areas like AI algorithms, digitalization of traditional Chinese medicine, and health monitoring. Collaborations with research institutions are underway to develop intelligent health service robot technologies, alongside the introduction of innovative massage chair products to the market [7].

Company Overview - OJIAWA (SZ 002614) announced an investor research meeting scheduled for September 1 and September 2, 2025, with participation from company representatives including Chen Yishu [1] - As of the report, OJIAWA has a market capitalization of 4.4 billion yuan [1] Revenue Composition - For the first half of 2025, OJIAWA's revenue composition is as follows: - Massage home appliances: 42.88% - Small massage appliances: 29.7% - Health environment products: 14.84% - Other products: 9.53% - Other business segments: 3.05% [1]